MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation antibodies, announced today that the Company received a milestone payment from Pfizer Inc. The amount of the payment was not disclosed. The payment was triggered by the initiation of human clinical trials of a novel monoclonal antibody therapeutic that was optimized using Xencor technologies under a March 2009 technology license agreement.
